SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.362
-0.588 (-14.97%)
Nov 7, 2024, 3:28 PM EST - Market open
SAB Biotherapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Net Income | -45.57 | -42.19 | -18.74 | -17.14 | 20.12 | -8.99 |
| Depreciation & Amortization | 4.95 | 3.75 | 3.29 | 1.65 | 0.55 | 0.32 |
| Loss (Gain) From Sale of Assets | 0.06 | 0.04 | -0.02 | -0.01 | -0 | 0 |
| Stock-Based Compensation | 2.8 | 2.42 | 2.67 | 2.31 | 1.3 | 0.37 |
| Other Operating Activities | 0.39 | 8.53 | -10.43 | 3.49 | - | 0 |
| Change in Accounts Receivable | - | 5.56 | 2.45 | 12.56 | -17.75 | -2.56 |
| Change in Accounts Payable | 0.23 | -2.7 | -0.78 | -2.94 | 5.21 | 1.56 |
| Change in Unearned Revenue | -1.51 | 1.32 | -0.1 | - | 0.1 | - |
| Change in Other Net Operating Assets | 0.44 | -1.85 | -1.81 | 2.06 | 0.48 | 0.08 |
| Operating Cash Flow | -38.21 | -25.12 | -23.46 | 1.99 | 10 | -9.21 |
| Operating Cash Flow Growth | - | - | - | -80.14% | - | - |
| Capital Expenditures | -0.35 | -0.2 | -2.17 | -10.94 | -12.73 | -0.61 |
| Sale of Property, Plant & Equipment | - | 0.04 | 0.08 | - | 0.01 | - |
| Investing Cash Flow | -21.36 | -0.15 | -2.09 | -10.94 | -12.72 | -0.61 |
| Long-Term Debt Issued | - | 0.77 | 1.24 | 2.84 | 0.66 | - |
| Short-Term Debt Repaid | - | - | - | - | -1.36 | - |
| Long-Term Debt Repaid | - | -1.16 | -2.42 | -1.3 | -0.21 | -0.62 |
| Total Debt Repaid | -1.44 | -1.16 | -2.42 | -1.3 | -1.58 | -0.62 |
| Net Debt Issued (Repaid) | -0.67 | -0.39 | -1.19 | 1.54 | -0.92 | -0.62 |
| Issuance of Common Stock | 59.68 | 59.66 | 7.76 | 0.01 | 9.9 | - |
| Other Financing Activities | -0.26 | - | -5.52 | 34.34 | - | -0.02 |
| Financing Cash Flow | 66.25 | 66.77 | 1.05 | 35.89 | 8.98 | 3.68 |
| Foreign Exchange Rate Adjustments | 0.07 | 0.02 | - | - | - | - |
| Net Cash Flow | 6.75 | 41.52 | -24.5 | 26.93 | 6.26 | -6.14 |
| Free Cash Flow | -38.56 | -25.32 | -25.63 | -8.96 | -2.73 | -9.82 |
| Free Cash Flow Margin | -2548.80% | -1130.71% | -107.20% | -14.71% | -4.94% | -285.41% |
| Free Cash Flow Per Share | -4.47 | -4.59 | -5.89 | -3.28 | -1.01 | -2.79 |
| Cash Interest Paid | 0.37 | 0.25 | 0.29 | - | - | 0.43 |
| Cash Income Tax Paid | - | - | 0.03 | - | - | - |
| Levered Free Cash Flow | -26.69 | -17.95 | -14.29 | 3.28 | -10.5 | - |
| Unlevered Free Cash Flow | -26.49 | -17.75 | -14.1 | 3.46 | -10.21 | - |
| Change in Net Working Capital | 1.15 | -0.07 | -0.18 | -18.81 | 12.17 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.